Close Menu

NEW YORK – Seattle-based Silverback Therapeutics on Wednesday announced that it had begun dosing patients in a Phase I clinical trial evaluating SBT6050, an agent comprising a TLR8 agonist conjugated to a HER2-directed monoclonal antibody.

The multicenter trial, which plans to enroll roughly 210 participants, will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of the agent as a treatment for patients with advanced HER2-expressing solid tumors.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.


NTRK fusions are oncogenic drivers in a variety of tumors.

Sponsored by

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Sponsored by

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.


In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.